Cargando…

Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy

Interleukin-2 (IL-2) associated cholecystopathy is a rare manifestation of IL-2 drug toxicity in the setting of cancer immunotherapy. While the imaging data and clinical presentation can easily mimic acute cholecystitis, the correct diagnosis can be made with the particular clinical history, thus av...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuppler, Kevin, Jeong, Daniel, Choi, Jung W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641551/ https://www.ncbi.nlm.nih.gov/pubmed/26576289 http://dx.doi.org/10.1177/2058460115579458

Ejemplares similares

Fulminant descending mediastinitis secondary to infectious mononucleosis
por: Fuller, G W, et al.
Publicado: (2018)

Vitreoretinal lymphoma, secondary to non-CNS systemic lymphoma, masquerading as an infectious retinitis
por: Reddy, Varun, et al.
Publicado: (2019)

Acute Encephalitis in an Adult with Diffuse Large B-Cell Lymphoma with Secondary Involvement of the Central Nervous System: Infectious or Non-Infectious Etiology?
por: Moonga, Surinder S., et al.
Publicado: (2017)

IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020)

Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
por: Alsemari, Muhannad A., et al.
Publicado: (2020)

Stanford Type A Aortic Dissection Secondary to Infectious Aortitis: A Case Report
por: Park, Bong Soo, et al.
Publicado: (2013)

Immunotherapy and vaccination against infectious diseases
por: Ebbers, Meinolf, et al.
Publicado: (2020)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Reactive infectious mucocutaneous eruption secondary to SARS-CoV-2
por: Ryder, C. Yoonhee, et al.
Publicado: (2021)

Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
por: Kuru, Sugabramya, et al.
Publicado: (2017)

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
por: de Gast, G C, et al.
Publicado: (2003)

Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020)

Recent advances in immunotherapies against infectious diseases
por: Ramamurthy, Dharanidharan, et al.
Publicado: (2020)

Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
por: Riccio, Anna Maria, et al.
Publicado: (2012)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Phenytoin Toxicity with High Dose, Concomitant Ascorbic Acid Dosing
por: Schuh, Michael J., et al.
Publicado: (2022)

Prospects of IL-2 in Cancer Immunotherapy
por: Choudhry, Hani, et al.
Publicado: (2018)

Heterodimeric IL-15 in Cancer Immunotherapy
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
por: Menon, Hari, et al.
Publicado: (2019)

Pseudohyperglycemia Secondary to High-Dose Intravenous Vitamin C Managed as Diabetic Ketoacidosis: An Endocrinological Catastrophe
por: Orija, Israel B., et al.
Publicado: (2020)

Early-stage corneal toxicity secondary to high-dose systemic cytarabine: a case report
por: Mito, Tsuyoshi, et al.
Publicado: (2023)

Engineering a variant of IL-17RA with high binding affinity to IL-17A for optimized immunotherapy
por: Armaghan, Fatemeh, et al.
Publicado: (2021)

Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab
por: Boni, Elisa, et al.
Publicado: (2016)

Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis
por: Matas, Jessica, et al.
Publicado: (2019)

Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
por: Clark, Joseph I., et al.
Publicado: (2018)

Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
por: Yang, Ying, et al.
Publicado: (2020)

Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
por: Kim, Ji-Hae, et al.
Publicado: (2021)

The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy
por: Wang, Chunli, et al.
Publicado: (2022)

Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy
por: Moral, Angel, et al.
Publicado: (2016)

Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
por: Zhou, Ting, et al.
Publicado: (2020)

Acute Pancreatitis Secondary to Ciprofloxacin Therapy in Patients with Infectious Colitis
por: Sung, Hye Young, et al.
Publicado: (2014)

IL-12 Family Cytokines in Cancer and Immunotherapy
por: Mirlekar, Bhalchandra, et al.
Publicado: (2021)

Improving cancer immunotherapy by targeting IL-1
por: Xiao, Zhilan, et al.
Publicado: (2021)

Anterior infectious necrotizing scleritis secondary to Pseudomonas aeruginosa infection following intravitreal ranibizumab injection
por: Coussa, Razek Georges, et al.
Publicado: (2016)

Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
por: Miao, Miao, et al.
Publicado: (2020)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

The Colon, the Source of Infectious and Non-Infectious Systemic Diseases
por: Cole, W. F.
Publicado: (1916)

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
por: Verra, N, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_fvgp4eefvakc7tvq5knpk7ifv3